Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)
CUSIP: 034569103
Q3 2023 13F Holders as of 30 Sep 2023
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 41,587,315
- Total 13F shares
- 7,050,491
- Share change
- +16,949
- Total reported value
- $21,560,562
- Price per share
- $3.06
- Number of holders
- 11
- Value change
- +$51,779
- Number of buys
- 4
- Number of sells
- 2
Quarterly Holders Quick Answers
What is CUSIP 034569103?
CUSIP 034569103 identifies ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 034569103:
Top shareholders of ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| 22NW, LP |
13F
|
Company |
12%
|
5,066,290
|
$11,905,782 | — | 30 Jun 2023 | |
| LVW Advisors, LLC |
13F
|
Company |
1.6%
|
672,331
|
$1,579,978 | — | 30 Jun 2023 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.2%
|
511,073
|
$1,201,022 | — | 30 Jun 2023 | |
| MANGROVE PARTNERS IM, LLC |
13F
|
Company |
0.96%
|
399,219
|
$938,165 | — | 30 Jun 2023 | |
| Praetorian PR LLC |
13F
|
Company |
0.43%
|
180,005
|
$423,012 | — | 30 Jun 2023 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.38%
|
156,203
|
$340,523 | — | 30 Jun 2023 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.04%
|
17,319
|
$40,700 | — | 30 Jun 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.04%
|
16,032
|
$37,675 | — | 30 Jun 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.02%
|
7,253
|
$17,045 | — | 30 Jun 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
6,101
|
$14,337 | — | 30 Jun 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
57
|
$134 | — | 30 Jun 2023 | |
| Simon Allen |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
70,246
|
— | — | 09 Dec 2022 | |
| Karah Herdman Parschauer |
3/4/5
|
Director |
—
class O/S missing
|
30,425
|
— | — | 21 Apr 2022 |
Institutional Holders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) as of Q3 2023
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2023 vs Q2 2023 Across Filers
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 Value $ | Q3 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.